Features Partner Sites Information LinkXpress
Sign In
Demo Company

Collaboration to Provide Clinical Trial Services in the United Kingdom for Study Data Capture, Processing, and Reporting

By BiotechDaily International staff writers
Posted on 25 Feb 2013
Print article
Merge Healthcare, Inc. (Chicago, IL, USA), a provider of clinical systems, announced that NorthWise Services (NWS; Sittingbourne, UK) has collaborated with Merge and selected eClinical OS (operating system) to gather, manage, and report on clinical trials data across all studies.

NWS is a specialist contract research organization (CRO) providing services in data management, statistics, and medical writing. Its services are complementary to the offerings of Merge, which has allowed a strong and active working partnership to develop.

“NWS has always supported products at the forefront of eClinical technology, but in the past this tended to be separated into different software tools for EDC, ePRO, IVR, etc.,” explained Dr. Philip North, managing director of NorthWise Services. “It is therefore very appealing now to be able to access a wide range of eClinical functions on a single web-based platform, with just one user login and password.”

Recognizing the potential benefits of eClinical OS in collecting, managing, and reporting clinical trials data across all stages, NWS has arranged to have its own eClinical OS-certified study builder, who can now build studies for clients using eClinical OS.

“We were pleased with how easy it was for our study builder to become qualified and certified in the use of eClinical OS,” continued Dr. North. “Merge provided NWS access to eClinical OS in a sandbox environment during the self-training process. Because of this, the qualification was quickly and entirely achieved, using only the extensive online training materials available within eClinical OS. The built-in training materials were intuitive and thorough. Our staff did not require any additional help from Merge—though that would have been available if needed.”

Cost transparency using eClinical OS’s self-service quoting tool was also a benefit to NWS. “The cost calculator tool has been very valuable,” added Dr. North. “Not only is Merge eClinical OS competitive in the eClinical marketplace, but this tool allows us to remain competitive when bidding on a new study with our sponsor clients.”

“With eClinical OS, NWS has deep visibility into the cost of its studies,” said Justin Dearborn, president of Merge Healthcare. “We designed a cost calculator into the system which allows our clients to generate their own quotes and create budget scenarios in real-time. This provides them with the decision support tools to balance options and costs.”

Merge eClinical OS provides end-to-end study support through a single, easy-to-use interface allowing clients to manage and run studies more effectively. It provides built-in study templates, libraries, and reports to help users create studies quickly and manage them effectively without technical, assistance. Merge eClinical OS works for the largest and smallest studies, has the flexibility to support trials in any phase, and captures any type of data, from any source, from any modality.

Merge’s enterprise and cloud-based systems for image intensive specialties provide access to any image, 24/7. Merge also provides health stations, clinical trials software and other health data and analytics solutions that engage consumers in their personal health.

NorthWise Services provides a range of services, including data management, statistics, and medical writing, to the biotechnology, pharmaceutical, and other industries, and other products and services through strategic working alliances.

Related Links:
Merge Healthcare
NorthWise Services

Print article



view channel
Image: Left: Green actin fibers create architecture of the cell. Right: With cytochalasin D added, actin fibers disband and reform in the nuclei (Photo courtesy of the University of North Carolina).

Actin in the Nucleus Triggers a Process That Directs Stem Cells to Mature into Bone

A team of cell biologists has discovered why treatment of mesenchymal stem cells (MSCs) with the mycotoxin cytochalasin D directs them to mature into bone cells (osteoblasts) rather than into fat cells... Read more


view channel

Molecular Light Shed on “Dark” Cellular Receptors

Scientists have created a new research tool to help find homes for orphan cell-surface receptors, toward better understanding of cell signaling, developing new therapeutics, and determining causes of drug side-effects. The approach may be broadly useful for discovering interactions of orphan receptors with endogenous, naturally... Read more

Lab Technologies

view channel
Image: The new ambr 15 fermentation micro-bioreactor system was designed to enhance microbial strain screening applications (Photo courtesy of Sartorius Stedim Biotech).

New Bioreactor System Streamlines Strain Screening and Culture

Biotechnology laboratories working with bacterial cultures will benefit from a new automated micro bioreactor system that was designed to enhance microbial strain screening processes. The Sartorius... Read more
Copyright © 2000-2015 Globetech Media. All rights reserved.